Enorama Pharma has entered a 2,500,000 USD loan agreement with its main shareholder, DS Global, to restore its equity position. The capital injection allows the board to propose continued operations at the upcoming second control meeting, effectively reversing the liquidation risk triggered on 13 February 2026.
The main owner DS Global lends USD 2,500,000 interest-free (optionally 9% p.a. if the EGM approves), maturing 31 December 2027, repayable only via share conversion at 0.4 SEK per share. This lets the loan count as equity, restoring equity above half the registered share capital, so the board can propose continued operations instead of liquidation at the second control meeting. For a company under a control balance sheet since 13 February 2026, survival is decisive, but dilution at the 0.4 SEK conversion price and the EGM approval condition temper the effect.
- ▲ USD 2,500,000 loan agreement signed today, 13 November 2026, with main owner DS Global
- ▲ Equity restored above half of registered share capital, removing the liquidation trigger
- ▼ The 9% annual interest requires approval at the extraordinary shareholders' meeting
- ▼ Possible repayment by set-off in an issue at 0.4 SEK per share implies significant dilution